Company: BDRX
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001214659-25-007915
Chunk: 3

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-15
Form: 424B3
Chunk 3
---
 Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: May 15, 2025 | Biodexa Pharmaceuticals PLC 
 By:                         | /s/ Stephen Stamp                                   |
|:-------------------|:----------------------------|:----------------------------------------------------|
|                    |                             | Stephen Stamp                                       |
|                    |                             | Chief Executive Officer and Chief Financial Officer |

Exhibit 10.1

[Name and address of warrant holder]

Re:

To Whom It May Concern:

Biodexa Pharmaceuticals PLC,
a public limited company organized under the laws of England and Wales
(the “”), is pleased to offer to you the opportunity to exercise the warrants set forth on your signature page
attached hereto (the “”) and held by you (the “”). The ordinary shares, nominal value
£0.00005 (“”) (in the form of American Depositary Shares) underlying the Warrants (“”) have been previously registered pursuant to registration statements on Form F-1 (the “”).
Capitalized terms not otherwise defined herein shall have the meanings set forth in the Warrants.

In consideration for cash
exercising the Warrants held by you as set forth on your signature page attached hereto on or before 9:00 a.m. (New York City time) on
May 15, 2025 (the “”), the Company hereby offers you a reduction of the exercise price of the Warrants
to US$0.31 per share. As such, upon accepting this offer, Section 2(b) of all Warrants issued pursuant to the Registration Statements
and held by you is hereby amended and restated as follows:

“The exercise price per ADS under
this Warrant shall be US$0.31, subject to adjustment hereunder (the “”).”

For the avoidance of doubt,
the Company will not be issuing warrants to the Holder to replace those being exercised pursuant to this letter agreement.

The Holder may accept this
offer by countersigning this letter below, with such acceptance constituting the Holder’s exercise of the number of Warrants as
set forth on your signature page attached hereto for an aggregate exercise price as set forth on the Holder’s signature page hereto
(the “”) on or before 9:00 a.m. (New York City time) on May 15, 2025. Notwithstanding anything
herein to the contrary, in the event